BioSpecifics Technologies (NASDAQ:BSTC) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday. The firm presently has a $50.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 16.47% from the stock’s previous close.

According to Zacks, “BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (FDA) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for potential use as pharmaceuticals. “

Several other research firms have also weighed in on BSTC. HC Wainwright reiterated a “buy” rating and set a $65.00 target price (down previously from $72.00) on shares of BioSpecifics Technologies in a research note on Monday, November 13th. lowered their target price on shares of BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th.

Shares of BioSpecifics Technologies (NASDAQ BSTC) traded down $0.39 during trading hours on Monday, hitting $42.93. 28,600 shares of the company were exchanged, compared to its average volume of 27,389. The company has a market capitalization of $308.63, a price-to-earnings ratio of 27.00 and a beta of 1.59. BioSpecifics Technologies has a fifty-two week low of $41.95 and a fifty-two week high of $58.79.

BioSpecifics Technologies (NASDAQ:BSTC) last issued its quarterly earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.01. BioSpecifics Technologies had a net margin of 42.40% and a return on equity of 19.11%. The business had revenue of $6.52 million during the quarter, compared to analyst estimates of $6.59 million. equities analysts predict that BioSpecifics Technologies will post 1.57 earnings per share for the current year.

A number of hedge funds have recently added to or reduced their stakes in BSTC. Los Angeles Capital Management & Equity Research Inc. bought a new stake in BioSpecifics Technologies during the third quarter valued at $223,000. SG Americas Securities LLC bought a new stake in BioSpecifics Technologies during the second quarter valued at $241,000. The Manufacturers Life Insurance Company increased its stake in BioSpecifics Technologies by 9.1% during the second quarter. The Manufacturers Life Insurance Company now owns 4,920 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 410 shares during the last quarter. Rhumbline Advisers increased its stake in BioSpecifics Technologies by 7.5% during the second quarter. Rhumbline Advisers now owns 6,667 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 466 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in BioSpecifics Technologies by 14.8% during the second quarter. Teachers Advisors LLC now owns 10,098 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 1,305 shares during the last quarter. Hedge funds and other institutional investors own 55.93% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/15/biospecifics-technologies-bstc-lifted-to-strong-buy-at-zacks-investment-research.html.

About BioSpecifics Technologies

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Get a free copy of the Zacks research report on BioSpecifics Technologies (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.